STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis (NASDAQ: IONS) EVP sells 37,277 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.

The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.

Positive

  • None.

Negative

  • None.
Insider Jenne Kyle
Role EVP, Chf GL Pdt Str Ofcr
Sold 37,277 shs ($2.83M)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 4,675 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 32,602 $0.00 --
Exercise Common Stock 32,602 $46.10 $1.50M
Sale Common Stock 21,191 $75.502 $1.60M
Sale Common Stock 16,086 $76.30 $1.23M
Exercise Common Stock 4,675 $34.69 $162K
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 14,025 shares (Direct); Common Stock — 48,991 shares (Direct)
Footnotes (1)
  1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jenne Kyle
(Last) (First) (Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CA 92010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chf GL Pdt Str Ofcr
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/10/2026 M 32,602 A $46.1 48,991 D
Common Stock 03/10/2026 S 21,191(1) D $75.502(2) 27,800 D
Common Stock 03/10/2026 S 16,086(1) D $76.3(3) 11,714 D
Common Stock 03/10/2026 M 4,675 A $34.69 16,389 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $34.69 03/10/2026 M 4,675 01/02/2026 01/01/2035 Common Stock 4,675 $0.0 14,025 D
Non-Qualified Stock Option (right to buy) $46.1 03/10/2026 M 32,602 02/26/2025 02/25/2034 Common Stock 32,602 $0.0 32,601 D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
By: Patrick R. O'Neil, attorney-in-fact For: Kyle Jenne 03/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Ionis Pharmaceuticals (IONS) EVP Kyle Jenne report in this Form 4?

EVP Kyle Jenne reported exercising stock options and selling shares of Ionis Pharmaceuticals Common Stock. He exercised 37,277 options and sold 37,277 shares in open-market trades, all on March 10, 2026, under a pre-established Rule 10b5-1 trading plan.

How many Ionis Pharmaceuticals (IONS) shares did Kyle Jenne sell and at what prices?

Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals Common Stock. The sales occurred in multiple transactions, with weighted average prices of $75.502 and $76.30 per share, reflecting execution across price ranges specified in the Form 4 footnotes.

How many Ionis Pharmaceuticals (IONS) options did Kyle Jenne exercise in this filing?

He exercised options covering 37,277 shares of Ionis Pharmaceuticals Common Stock. These included 4,675 options with a $34.69 exercise price and 32,602 options with a $46.10 exercise price, both originally granted as non-qualified stock options with future expiration dates.

Were Kyle Jenne’s Ionis Pharmaceuticals (IONS) stock sales pre-planned?

Yes. The Form 4 states that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Kyle Jenne on December 8, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing in evaluating the transactions.

What is Kyle Jenne’s remaining Ionis Pharmaceuticals (IONS) share ownership after these transactions?

After the reported option exercises and sales, Kyle Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock. This figure reflects his post-transaction position as shown in the Form 4, indicating he retained a meaningful equity stake in the company.

What types of securities were involved in Kyle Jenne’s Ionis Pharmaceuticals (IONS) Form 4?

The filing involves non-qualified stock options and Common Stock of Ionis Pharmaceuticals. Jenne exercised options into Common Stock and then sold Common Stock in open-market transactions, with all ownership reported as direct rather than through an intermediary entity.